ReviewTranslational lung cancer research2025
Research progress on lung cancer complicated with pulmonary tuberculosis: a narrative review.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clinical characteristics and surgical outcomes of uniportal video-assisted thoracoscopic surgery for lung cancer patients with concomitant pulmonary tuberculosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Development and validation of a habitat-based computed tomography radiomics model for differentiating isolated lung cancer, isolated tuberculoma, and coexistence of tuberculosis with lung cancer: a dual-center retrospective study.Translational lung cancer research · 2026Article
- A Case of Pancreatic Cancer Complicated by Active Pulmonary Tuberculosis Successfully Managed through a Multidisciplinary Treatment Strategy.Surgical case reports · 2026Article
- Temporal Disease Sequence and Prognostic Outcomes in Patients with Coexisting Lung Cancer and Tuberculosis: A 123-Patient Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Pulmonary tuberculosis (PTB) and lung cancer (LC) are both serious health threats and have a complex relationship. Research has shown that tuberculosis (TB) may induce LC through chronic inflammation. TB infection is also more common in LC patients than in the general population. Patients with LC and TB have a higher rate of misdiagnosis, missed diagnosis, and a worse prognosis. Thus, the diagnosis and treatment of patients with LC and TB are highly challenging. This narrative review aims to provide some information for clarification on the relationship between LC and TB. Methods: We searched for retrospective cohort studies, observational studies, systematic reviews, and meta-analyses published between the database's inception and 2024 to retrieve relevant articles on TB and LC from the PubMed/MEDLINE database. Key Content and Findings: We outline the latest research on the relationship between pulmonary TB and LC, potential biological mechanisms, as well as the co-treatment of TB and the tumor. Conclusions: Chronic inflammatory stimulation, scar formation, DNA damage, immune dysfunction, and other mechanisms caused by TB are associated with the development and progression of LC. LC may also reactivate TB. Currently, there is no standard diagnosis and treatment plan for co-existent TB and LC. The fundamental principle of patient management is to balance anti-tumor and anti-TB treatments based on the patient's physical condition and make comprehensive intervention decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.